Tisagenlecleucel for Treatment of Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia (R/R B-All): A Systematic Review of Cost-Effectiveness Analysis

Tisagenlecleucel is a new immunological therapy in refractory or relapsed B-cell lymphoblastic leukemia with high expense. Objective: To assess the quality as well as analyze characteristics and results of cost-effectiveness analysis (CEA) of tisagenlecleucel immunological therapy in children with R/R B-ALL. Method: To analyze systematic review of articles published during the period of 2017-2023 in Pubmed, ScienceDirect, GoogleScholar, Cochrane databases. Result: 10 selected studies were carried out in 8 nations with different cost units and discount rates. Compared therapies were standard therapy of each country included Blinatumomab, Clo-C, Clo-M, FLA-IDA, FLAG-IDA. Of 10 studies, 70% was considered cost-effectiveness, 20% non-conclusion and only 10% not cost-effectiveness. Conclusion: Tisagenlecleucel’s cost is the highest among compared therapies but it can be cost-effective in a nation with WTP threshold of $100.000-$150.000. Keywords: Systematic review, cost-effective, tisagenlecleucel, CAR-T, acute lymphoblastic leukemia.